Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Publication/Presentation Date
10-1-2023
Volume
37
Issue
10
First Page
1211
Last Page
1211
ISSN
1468-3083
Published In/Presented At
Guttman-Yassky, E., Bahadori, L., Brooks, L., Clark, K. L., Grindebacke, H., Ho, C. N., Katial, R., Pham, T. H., Walton, C., Datto, C. J., & HILLIER study group† (2023). Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial. Journal of the European Academy of Dermatology and Venereology : JEADV, 37(10), e1211–e1214. https://doi.org/10.1111/jdv.19195
Disciplines
Medicine and Health Sciences
PubMedID
37178404
Department(s)
Department of Medicine
Document Type
Article
COinS